US 7,888,051 B2Granted

Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues

AssigneeCancer Prevention and Cure, Ltd.

InventorsRobert T. Streeper, Elzbieta Izbicka, Sung H. Baek

Life of this patent

Estimating the term…

Loading patent…

Abstract

A method of identifying altered biomarker expression levels in a human serum specimen to diagnose asthma or non-small celled lung cancers in humans. The existence of asthma or non-small celled lung cancers in a patient can be determined by subjecting a blood sample from the patient to a simple blood test to determine the expression levels of certain specific biomarkers. The expression levels of the specific biomarkers are compared to ranges of expression levels for the same biomarkers which are indicative of individuals known to have asthma, non-small cell lung cancers, or neither. Comparing the expression levels will determine the existence or non-existence of asthma or non-small cell lung cancer.

Claims34

Dependent claims

A method of identifying altered biomarker expression levels in a human serum specimen to diagnose pathologies of human lung tissues comprising:

obtaining said human serum specimen to be tested for said altered biomarker expression levels;
selecting biomarkers for measuring said biomarker expression levels in said human serum specimen;
measuring said biomarker expression levels in said human serum specimen, said measuring step comprising dividing said human serum specimen into aliquots, placing said aliquots of said human serum specimen into a plurality of wells on a microplate, said plurality of wells having antibody derivitized dye coded beads therein to detect the presence of a particular biomarker selected during said selecting step, subjecting said microplate with said aliquots of said human serum specimens to a bead-based multiplexing assay, observing and measuring the resulting said biomarker expression levels from said bead-based multiplexing assay;
determining substantially unaltered biomarker expression levels for the same biomarkers selected in said selecting step, said unaltered biomarker expression levels being determined from a population of human serum specimens not having said pathologies of human lung tissues;
comparing said biomarker expression levels of said human serum specimen obtained in said obtaining step to said unaltered biomarker expression levels from said population of human serum specimens;
determining whether said biomarker expression levels of said human serum specimen are altered;
wherein said altered biomarker expression levels are indicative of said pathologies of said human lung tissues;
and
wherein said pathologies of said human lung tissues comprise non-small cell lung cancers and asthma.

6 more elements

A method of identifying biomarkers present in human serum which are indicative of pathologies of human lung tissues when expression levels of said biomarkers are altered in comparison to expression levels of the same said biomarkers in serum from humans not having said pathologies, said method comprising the steps of:

first obtaining a plurality of human sera from a population of humans without said pathologies of said human lung tissues;
second obtaining a plurality of human sera from a population of humans with asthma;
third obtaining a plurality of human sera from a population of humans with non-small cell lung cancers;
selecting said biomarkers for measuring said expression levels of said biomarkers;
first measuring said expression levels of said biomarkers from said population of humans without said pathologies of said human lung tissues;
second measuring said expression levels of said biomarkers from said population of humans with said asthma;
third measuring said expression levels of said biomarkers from said population of humans with said non-small cell lung cancers;
first comparing said expression levels of said biomarkers from said population of humans with said asthma to said expression levels of said biomarkers from said population of humans without said pathologies of said human lung tissues;
second comparing said expression levels of said biomarkers from said population of humans with said non-small cell lung cancers to said expression levels of said biomarkers from said population of humans without said pathologies of said human lung tissues;
third comparing said expression levels of said biomarkers from said population of humans with said asthma to said expression levels of said biomarkers from said population of humans with said non-small cell lung cancer;
identifying which of said biomarkers selected during said selecting step are indicative of said pathologies of said human lung tissues;
and
wherein said pathologies comprise said asthma and said non-small cell lung cancers.

10 more elements

Dependencies are inferred from the claim text.